Inhibrx, Inc.

41 articles about Inhibrx, Inc.

• Inhibrx To Host Webcast to Announce Regulatory Pathway for INBRX-101, its Optimized Recombinant Human AAT-Fc Protein for the Treatment of Alpha-1 Antitrypsin Deficiency

  10/3/2022

  Inhibrx, Inc. announced that it will host a live webcast presentation on Tuesday, October 4, 2022 at 5:30 a.m. PT to announce the regulatory pathway for INBRX-101 for the treatment of patients with alpha-1 antitrypsin deficiency, or AATD.

• European Medicines Agency Grants Orphan Drug Designation to INBRX-109 for the Treatment of Chondrosarcoma

  8/15/2022

  Inhibrx, Inc. (Nasdaq: INBX), today announced that the European Commission ("EC"), based on a positive opinion issued by the European Medicines Agency ("EMA"), has granted orphan medicinal product designation to INBRX-109 for the treatment of chondrosarcoma.

• Inhibrx Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights

  8/8/2022

  Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development and a strong emerging pipeline, today reported financial results for the second quarter of 2022 and provided an update on recent corporate highlights.

• Inhibrx Announces Details of Presentation at 2022 ASCO Annual Meeting

  5/19/2022

  Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development and an emerging pre-clinical pipeline, announced today that it will be presenting details on the trial design for the INBRX-109 Phase 2 potentially registration-enabling trial in conventional chondrosarcoma at the 2022 American Society of Clinical Oncology ("ASCO") Annual Meeting.

• INBRX-101 Shows Favorable Safety Profile in Patients with Alpha-1 Antitrypsin Deficiency and Demonstrates Potential to Achieve Normal Functional Alpha-1 Antitrypsin Levels with Monthly Dosing

  5/16/2022

  Inhibrx Inc. (Nasdaq: INBX), today announced topline results from a Phase 1 clinical trial evaluating the safety, pharmacokinetics ("PK") and pharmacodynamics ("PD") of INBRX-101, an optimized recombinant human AAT-Fc fusion protein, in patients with alpha-1 antitrypsin deficiency ("AATD").

• Inhibrx To Host Webcast Presentation of Topline Results from the Phase 1 Trial of INBRX-101, its Optimized Recombinant Human AAT-Fc Protein for the Treatment of Alpha-1 Antitrypsin Deficiency

  5/12/2022

  Inhibrx, Inc. (Nasdaq: INBX), today announced that it will host a live webcast presentation on Monday, May 16, 2022 at 1:30 p.m. PT to provide topline results from a Phase 1 clinical trial evaluating the safety and pharmacokinetics of INBRX-101 in patients with alpha-1 antitrypsin deficiency, or AATD.

• Inhibrx Reports First Quarter 2022 Financial Results and Recent Corporate Highlights

  5/9/2022

  Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development and a strong emerging pipeline, today reported financial results for the first quarter of 2022 and provided an update on recent corporate highlights.

• Inhibrx Announces Formation of Scientific Advisory Board for INBRX-101

  4/25/2022

  Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development and a strong emerging pipeline, today announced the formation of a Scientific Advisory Board ("SAB") for its INBRX-101 program for the treatment of alpha-1 antitrypsin deficiency ("AATD").

• Inhibrx to Present INBRX-101 Data at ATS 2022 Annual Meeting

  4/5/2022

  Inhibrx, Inc. announced today that late-breaking data from INBRX-101 will be presented at the American Thoracic Society ("ATS") 2022 Conference to be held May 13th - 18th , 2022 in San Francisco, CA.

• Inhibrx Announces Details of Presentations at 2022 AACR Annual Meeting

  3/24/2022

  Inhibrx, Inc. announced that data from INBRX-121 and INBRX-130 will be presented at the 2022 American Association for Cancer Research Annual Meeting to be held April 8th- 13th, 2022 in New Orleans, LA.

• Inhibrx Receives FDA Orphan-Drug Designation for INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency

  3/3/2022

  Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development and a strong emerging pipeline, today announced that the U.S. Food and Drug Administration, or FDA, has granted orphan-drug designation for INBRX-101 for the treatment of alpha-1 antitrypsin deficiency, or AATD.

• Inhibrx Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Recent Corporate Highlights

  2/28/2022

  Inhibrx, Inc. reported financial results for the fourth quarter and fiscal year 2021 and provided an update on recent corporate highlights.

• Inhibrx Announces Amended Loan Agreement with Oxford

  2/22/2022

  Inhibrx, Inc., a biotechnology company with four clinical programs in development and a strong emerging pipeline, announced that it has amended its loan and security agreement with Oxford Finance LLC.

• Inhibrx Announces Initial Phase 1 Dose Escalation Results for INBRX-106, a Novel Hexavalent OX40 Agonist, in Combination with Keytruda® (Pembrolizumab) Along with Updated Single Agent Data

  1/4/2022

  Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development and a strong emerging pipeline, today announced initial results from Part 3 (combination dose escalation) of the 4-part Phase 1 trial of INBRX-106, a novel hexavalent OX40 agonist, in combination with Keytruda®, in development for the treatment of patients with solid tumors.

• Inhibrx Receives FDA Orphan-Drug Designation for INBRX-109 in Chondrosarcoma

  12/1/2021

  Inhibrx, Inc today announced that the U.S. Food and Drug Administration, or FDA, has granted orphan-drug designation for INBRX-109 for the treatment of chondrosarcoma.

• Inhibrx Reports Third Quarter 2021 Financial Results and Recent Corporate Highlights

  11/9/2021

  Inhibrx, Inc.Inhibrx, Inc., a biotechnology company with four clinical programs in development and a strong emerging pipeline, reported financial results for the third quarter of 2021 and provided an update on recent corporate highlights.

• Inhibrx Announces Presentations at SITC 2021

  11/3/2021

  Inhibrx, Inc. announced today that the Company will be presenting three poster presentations at the Society for Immunotherapy of Cancer's (SITC) annual meeting, to be held in Washington, D.C.

• Inhibrx Announces Participation in Upcoming Scientific and Investor Conferences - Nov 01, 2021

  11/1/2021

  Inhibrx, Inc., a biotechnology company with four clinical programs in development and an emerging pre-clinical pipeline, announced that the Company will be presenting at the Connective Tissue Oncology Society, or CTOS, 2021 Virtual Annual Meeting taking place November 10-13, 2021.

• Inhibrx Strengthens Leadership Team with Three Key Executive Hires and Announces Appointment of Kristiina Vuori, M.D., Ph.D. to its Board of Directors

  10/28/2021

  Inhibrx, Inc. (Nasdaq: INBX), announced the appointment of three key executives: David Matly, M.B.A., as Chief Commercial Officer; David Kao, PharmD, M.B.A., RPh, as Vice President of Regulatory Affairs; and Jack Tsai, M.D., M.B.A., as Vice President of Business Development.

• INBRX-101 Shows Favorable Safety Profile in Patients with Alpha-1 Antitrypsin Deficiency and Demonstrates the Potential to Achieve Normal Alpha-1 Antitrypsin Levels with Monthly Dosing

  10/12/2021

  Inhibrx, Inc. today announced interim results from a Phase 1 clinical trial evaluating the safety and pharmacokinetics of INBRX-101, an optimized recombinant human AAT-Fc fusion protein, in patients with alpha-1 antitrypsin deficiency, or AATD.